- Cardiol Therapeutics (CRDL) has received clearance from the FDA and regulatory agencies in Brazil and Mexico to modify the inclusion criteria for the LANCER trial
- The amendments will broaden the population of patients eligible for enrollment in the trial
- LANCER is designed to evaluate the efficacy and safety of CardiolRx™
- Cardiol CEO David Elsley sat down with Shoran Devi to discuss the news
- Cardiol Therapeutics is a clinical stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease
- Shares in Cardiol Therapeutics Inc. (CRDL) opened trading at C$2.13
Cardiol Therapeutics (CRDL) has received clearance to modify the inclusion criteria for the LANCER trial.
The clearance from the FDA and regulatory agencies in Brazil and Mexico will allow Cardiol to broaden the population of patients eligible for enrollment in the trial.
The company also announced plans to expand the clinical trial infrastructure to include up to an additional 20 clinical research centers.
Cardiol CEO David Elsley sat down with Shoran Devi to discuss the news.
LANCER is designed to evaluate the efficacy and safety of CardiolRx™ as a cardiopulmonary protective therapy to reduce mortality and major cardiovascular events in patients hospitalized with COVID-19.
These updates are expected to remove key barriers to participation in LANCER as well as expand the eligible patient pool and include the following: (i) vaccinated people may be enrolled; (ii) use of therapies approved for the treatment of COVID-19 under an emergency use authorization label is permitted; and (iii) prior history of smoking or obesity, both CVD risk factors prevalent in younger patients, will allow entry into the trial.
The company expects the LANCER trial to achieve over 50 per cent patient recruitment by the end of the first half of 2022 and to complete full patient enrollment during the second half of 2022.
Cardiol Therapeutics Inc.(CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease.
Shares in Cardiol Therapeutics Inc. (CRDL) opened trading at C$2.13.